Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Myocardial Infarction, Cerebral Infarction. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
Overview
Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.
Detailed description
Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.
Primary outcome measures
- Number of Participants with major adverse events [Time frame: 5 years]
Secondary outcome measures (2)
- blood routine, glucose and lipid profile; ECG; [Time frame: 5 years]
- serum adiponectin concentration, activity and isoforms [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- available for 5 years of follow-up study
Exclusion criteria
- Death caused other than cardiovascular and cerebralvascular diseases till the study ends
- Floating Population
- Pregnancy, lactation, or child bearing women
- Tumor
- Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL
- Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L)
- Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Xijing Hospital — Xi'an
Publications
- Gao C, Zhao S, Lian K, Mi B, Si R, Tan Z, Fu F, Wang S, Wang R, Ma X, Tao L. C1q/TNF-related protein 3 (CTRP3) and 9 (CTRP9) concentrations are decreased in patients with heart failure and are associated with increased morbidity and mortality. BMC Cardiovasc Disord. 2019 Jun 10;19(1):139. doi: 10.1186/s12872-019-1117-0. PMID 31182031
Identifiers
NCT: NCT01372800 · xj050503